<P><B>Abstract</B></P><P>To identify prognostic markers in nonmuscle invasive bladder cancer (NMIBC), the combined effect of <I>RUNX3</I> and <I>MGC17624</I> for predicting NMIBC progression was as...
http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
https://www.riss.kr/link?id=A107555073
Ha, Yun‐ ; Sok ; Kim, Ji Sang ; Yoon, Hyung‐ ; Yoon ; Jeong, Pildu ; Kim, Tae‐ ; Hwan ; Yun, Seok‐ ; Joong ; Lee, Sang‐ ; Cheol ; Kim, Gi‐ ; Young ; Choi, Yung‐ ; Hyun ; Moon, Sung‐ ; Kwon ; Yi Kim, Isaac ; Kim, Wun‐ ; Jae
2012
-
SCOPUS,SCIE
학술저널
501-507(7쪽)
0
상세조회0
다운로드다국어 초록 (Multilingual Abstract)
<P><B>Abstract</B></P><P>To identify prognostic markers in nonmuscle invasive bladder cancer (NMIBC), the combined effect of <I>RUNX3</I> and <I>MGC17624</I> for predicting NMIBC progression was as...
<P><B>Abstract</B></P><P>To identify prognostic markers in nonmuscle invasive bladder cancer (NMIBC), the combined effect of <I>RUNX3</I> and <I>MGC17624</I> for predicting NMIBC progression was assessed. <I>RUNX3</I> promoter methylation was examined using methylation specific‐polymerase chain reaction (MS‐PCR). <I>MGC17624</I> mRNA expression was evaluated by real‐time PCR. Patients were divided into three groups according to the status of the two genes and the prognostic effects of these markers were evaluated. The median follow‐up period was 57.8 months (range, 9.1–189.7). The mRNA expression level of <I>MGC17624</I> was significantly lower in patients with positive <I>RUNX3</I> methylation than in those with negative methylation (<I>p</I> = 0.047). Kaplan–Meier estimates showed significant differences in time‐to‐progression between the genetic combination predictors (log‐rank test; <I>p</I> < 0.001). Patients with a poor predictive combination were at a significantly higher risk for progression [Hazard ratio (HR), 22.579] than patients with a good predictive combination in multivariate Cox regression analysis. In the subgroup analysis, a poor predictive combination accurately estimated progression in patients with intravesical therapy (HR, 20.081) and in those who experienced recurrence (HR, 54.233). Assessment of the status of <I>RUNX3</I> and <I>MGC17624</I> in combination was identified as a reliable method for predicting NMIBC progression.</P>